Comparable results were obtained after combined hsBCL9z96 and anti-CTLA-4 treatment was administered to established CT26 tumor-bearing mice (TGI = 74.8%, Supplementary Fig. 14c, d) and to established MC38 tumor-bearing mice (TGI = 78.4%, Supplementary Fig. 14e, f). This evidence concerns the gene DDX53 and neoplasm.